Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for chronic neuropathic pain after spinal cord injury
ACTRN12622000634774Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Neuralgia and spinal cord injury (SCI) (2 arms), sponsored by University of Sydney. Primary endpoint: Change in average intensity of ongoing pain on Visual Analogue Scale. Started Jul 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
Neuralgiaspinal cord injury (SCI)
Beyond the preview
Go deeper on ACTRN12622000634774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000634774.